Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

There are errors in the Funding section. The correct funding information is as follows: This work was funded by the Muscular Dystrophy Association of USA (MDA), the Fight-MG grant of the FP7 EC program, the Association Francaise contre les Myopathies (AFM), the European Commission (Contract No 242210), the Greek GSRT (program “Aristeia”), FP-7 Research potential Program/Regpot SEEDRUG of University of Patras (Grant number: EU FP7 REGPOT CT-2011-285950) and by the Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) Research Funding Program: THALES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Reference

  1. 1. Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ (2014) Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients. PLoS ONE 9(9): e108327. pmid:25259739